Global Prostate Cancer Diagnostics Market Size, Manufacturers, Growth Analysis Industry Forecast to 2030
Summary
The prostate is a walnut-sized gland located behind the base of a man’s penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.
Prostate Cancer Diagnostics refers to using PSA, rectal exam, biopsy and others to diagnostic whether patients with breast cancer.
According to APO Research, The global Prostate Cancer Diagnostics market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
North American market for Prostate Cancer Diagnostics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Prostate Cancer Diagnostics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Prostate Cancer Diagnostics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Prostate Cancer Diagnostics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Prostate Cancer Diagnostics include OPKO, Genomic Health, Abbott, Beckman Coulter, Siemens Healthcare, bioMeriux, Roche, MDx Health and DiaSorin, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Prostate Cancer Diagnostics, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Prostate Cancer Diagnostics, also provides the value of main regions and countries. Of the upcoming market potential for Prostate Cancer Diagnostics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Prostate Cancer Diagnostics revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Prostate Cancer Diagnostics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Prostate Cancer Diagnostics company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Prostate Cancer Diagnostics segment by Company
1. To analyze and research the global Prostate Cancer Diagnostics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Prostate Cancer Diagnostics key companies, revenue, market share, and recent developments.
3. To split the Prostate Cancer Diagnostics breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Prostate Cancer Diagnostics market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Prostate Cancer Diagnostics significant trends, drivers, influence factors in global and regions.
6. To analyze Prostate Cancer Diagnostics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Prostate Cancer Diagnostics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Prostate Cancer Diagnostics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Prostate Cancer Diagnostics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Prostate Cancer Diagnostics industry.
Chapter 3: Detailed analysis of Prostate Cancer Diagnostics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Prostate Cancer Diagnostics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Prostate Cancer Diagnostics in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
The prostate is a walnut-sized gland located behind the base of a man’s penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.
Prostate Cancer Diagnostics refers to using PSA, rectal exam, biopsy and others to diagnostic whether patients with breast cancer.
According to APO Research, The global Prostate Cancer Diagnostics market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
North American market for Prostate Cancer Diagnostics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Prostate Cancer Diagnostics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Prostate Cancer Diagnostics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Prostate Cancer Diagnostics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Prostate Cancer Diagnostics include OPKO, Genomic Health, Abbott, Beckman Coulter, Siemens Healthcare, bioMeriux, Roche, MDx Health and DiaSorin, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Prostate Cancer Diagnostics, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Prostate Cancer Diagnostics, also provides the value of main regions and countries. Of the upcoming market potential for Prostate Cancer Diagnostics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Prostate Cancer Diagnostics revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Prostate Cancer Diagnostics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Prostate Cancer Diagnostics company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Prostate Cancer Diagnostics segment by Company
- OPKO
- Genomic Health
- Abbott
- Beckman Coulter
- Siemens Healthcare
- bioMeriux
- Roche
- MDx Health
- DiaSorin
- Myriad Genetics
- Ambry Genetics
- Tumor Biomarker Tests
- Imaging
- Biopsy
- Other
- Age Below 55
- Age 55-75
- Age Above 75
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
1. To analyze and research the global Prostate Cancer Diagnostics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Prostate Cancer Diagnostics key companies, revenue, market share, and recent developments.
3. To split the Prostate Cancer Diagnostics breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Prostate Cancer Diagnostics market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Prostate Cancer Diagnostics significant trends, drivers, influence factors in global and regions.
6. To analyze Prostate Cancer Diagnostics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Prostate Cancer Diagnostics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Prostate Cancer Diagnostics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Prostate Cancer Diagnostics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Prostate Cancer Diagnostics industry.
Chapter 3: Detailed analysis of Prostate Cancer Diagnostics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Prostate Cancer Diagnostics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Prostate Cancer Diagnostics in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
1 MARKET OVERVIEW
1.1 Product Definition
1.2 Global Prostate Cancer Diagnostics Market Size, 2019 VS 2023 VS 2030
1.3 Global Prostate Cancer Diagnostics Market Size (2019-2030)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 PROSTATE CANCER DIAGNOSTICS MARKET DYNAMICS
2.1 Prostate Cancer Diagnostics Industry Trends
2.2 Prostate Cancer Diagnostics Industry Drivers
2.3 Prostate Cancer Diagnostics Industry Opportunities and Challenges
2.4 Prostate Cancer Diagnostics Industry Restraints
3 PROSTATE CANCER DIAGNOSTICS MARKET BY COMPANY
3.1 Global Prostate Cancer Diagnostics Company Revenue Ranking in 2023
3.2 Global Prostate Cancer Diagnostics Revenue by Company (2019-2024)
3.3 Global Prostate Cancer Diagnostics Company Ranking, 2022 VS 2023 VS 2024
3.4 Global Prostate Cancer Diagnostics Company Manufacturing Base & Headquarters
3.5 Global Prostate Cancer Diagnostics Company, Product Type & Application
3.6 Global Prostate Cancer Diagnostics Company Commercialization Time
3.7 Market Competitive Analysis
3.7.1 Global Prostate Cancer Diagnostics Market CR5 and HHI
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2023
3.7.3 2023 Prostate Cancer Diagnostics Tier 1, Tier 2, and Tier
3.8 Mergers & Acquisitions, Expansion
4 PROSTATE CANCER DIAGNOSTICS MARKET BY TYPE
4.1 Prostate Cancer Diagnostics Type Introduction
4.1.1 Tumor Biomarker Tests
4.1.2 Imaging
4.1.3 Biopsy
4.1.4 Other
4.2 Global Prostate Cancer Diagnostics Sales Value by Type
4.2.1 Global Prostate Cancer Diagnostics Sales Value by Type (2019 VS 2023 VS 2030)
4.2.2 Global Prostate Cancer Diagnostics Sales Value by Type (2019-2030)
4.2.3 Global Prostate Cancer Diagnostics Sales Value Share by Type (2019-2030)
5 PROSTATE CANCER DIAGNOSTICS MARKET BY APPLICATION
5.1 Prostate Cancer Diagnostics Application Introduction
5.1.1 Age Below
5.1.2 Age 55-75
5.1.3 Age Above
5.2 Global Prostate Cancer Diagnostics Sales Value by Application
5.2.1 Global Prostate Cancer Diagnostics Sales Value by Application (2019 VS 2023 VS 2030)
5.2.2 Global Prostate Cancer Diagnostics Sales Value by Application (2019-2030)
5.2.3 Global Prostate Cancer Diagnostics Sales Value Share by Application (2019-2030)
6 PROSTATE CANCER DIAGNOSTICS MARKET BY REGION
6.1 Global Prostate Cancer Diagnostics Sales Value by Region: 2019 VS 2023 VS 2030
6.2 Global Prostate Cancer Diagnostics Sales Value by Region (2019-2030)
6.2.1 Global Prostate Cancer Diagnostics Sales Value by Region: 2019-2024
6.2.2 Global Prostate Cancer Diagnostics Sales Value by Region (2025-2030)
6.3 North America
6.3.1 North America Prostate Cancer Diagnostics Sales Value (2019-2030)
6.3.2 North America Prostate Cancer Diagnostics Sales Value Share by Country, 2023 VS 2030
6.4 Europe
6.4.1 Europe Prostate Cancer Diagnostics Sales Value (2019-2030)
6.4.2 Europe Prostate Cancer Diagnostics Sales Value Share by Country, 2023 VS 2030
6.5 Asia-Pacific
6.5.1 Asia-Pacific Prostate Cancer Diagnostics Sales Value (2019-2030)
6.5.2 Asia-Pacific Prostate Cancer Diagnostics Sales Value Share by Country, 2023 VS 2030
6.6 Latin America
6.6.1 Latin America Prostate Cancer Diagnostics Sales Value (2019-2030)
6.6.2 Latin America Prostate Cancer Diagnostics Sales Value Share by Country, 2023 VS 2030
6.7 Middle East & Africa
6.7.1 Middle East & Africa Prostate Cancer Diagnostics Sales Value (2019-2030)
6.7.2 Middle East & Africa Prostate Cancer Diagnostics Sales Value Share by Country, 2023 VS 2030
7 PROSTATE CANCER DIAGNOSTICS MARKET BY COUNTRY
7.1 Global Prostate Cancer Diagnostics Sales Value by Country: 2019 VS 2023 VS 2030
7.2 Global Prostate Cancer Diagnostics Sales Value by Country (2019-2030)
7.2.1 Global Prostate Cancer Diagnostics Sales Value by Country (2019-2024)
7.2.2 Global Prostate Cancer Diagnostics Sales Value by Country (2025-2030)
7.3 USA
7.3.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.3.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.3.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.4 Canada
7.4.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.4.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.4.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.5 Germany
7.5.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.5.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.5.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.6 France
7.6.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.6.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.6.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.7 U.K.
7.7.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.7.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.7.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.8 Italy
7.8.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.8.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.8.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.9 Netherlands
7.9.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.9.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.9.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.10 Nordic Countries
7.10.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.10.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.10.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.11 China
7.11.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.11.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.11.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.12 Japan
7.12.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.12.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.12.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.13 South Korea
7.13.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.13.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.13.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.14 Southeast Asia
7.14.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.14.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.14.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.15 India
7.15.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.15.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.15.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.16 Australia
7.16.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.16.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.16.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.17 Mexico
7.17.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.17.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.17.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.18 Brazil
7.18.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.18.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.18.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.19 Turkey
7.19.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.19.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.19.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.20 Saudi Arabia
7.20.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.20.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.20.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.21 UAE
7.21.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.21.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.21.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
8 COMPANY PROFILES
8.1 OPKO
8.1.1 OPKO Comapny Information
8.1.2 OPKO Business Overview
8.1.3 OPKO Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
8.1.4 OPKO Prostate Cancer Diagnostics Product Portfolio
8.1.5 OPKO Recent Developments
8.2 Genomic Health
8.2.1 Genomic Health Comapny Information
8.2.2 Genomic Health Business Overview
8.2.3 Genomic Health Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
8.2.4 Genomic Health Prostate Cancer Diagnostics Product Portfolio
8.2.5 Genomic Health Recent Developments
8.3 Abbott
8.3.1 Abbott Comapny Information
8.3.2 Abbott Business Overview
8.3.3 Abbott Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
8.3.4 Abbott Prostate Cancer Diagnostics Product Portfolio
8.3.5 Abbott Recent Developments
8.4 Beckman Coulter
8.4.1 Beckman Coulter Comapny Information
8.4.2 Beckman Coulter Business Overview
8.4.3 Beckman Coulter Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
8.4.4 Beckman Coulter Prostate Cancer Diagnostics Product Portfolio
8.4.5 Beckman Coulter Recent Developments
8.5 Siemens Healthcare
8.5.1 Siemens Healthcare Comapny Information
8.5.2 Siemens Healthcare Business Overview
8.5.3 Siemens Healthcare Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
8.5.4 Siemens Healthcare Prostate Cancer Diagnostics Product Portfolio
8.5.5 Siemens Healthcare Recent Developments
8.6 bioMeriux
8.6.1 bioMeriux Comapny Information
8.6.2 bioMeriux Business Overview
8.6.3 bioMeriux Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
8.6.4 bioMeriux Prostate Cancer Diagnostics Product Portfolio
8.6.5 bioMeriux Recent Developments
8.7 Roche
8.7.1 Roche Comapny Information
8.7.2 Roche Business Overview
8.7.3 Roche Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
8.7.4 Roche Prostate Cancer Diagnostics Product Portfolio
8.7.5 Roche Recent Developments
8.8 MDx Health
8.8.1 MDx Health Comapny Information
8.8.2 MDx Health Business Overview
8.8.3 MDx Health Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
8.8.4 MDx Health Prostate Cancer Diagnostics Product Portfolio
8.8.5 MDx Health Recent Developments
8.9 DiaSorin
8.9.1 DiaSorin Comapny Information
8.9.2 DiaSorin Business Overview
8.9.3 DiaSorin Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
8.9.4 DiaSorin Prostate Cancer Diagnostics Product Portfolio
8.9.5 DiaSorin Recent Developments
8.10 Myriad Genetics
8.10.1 Myriad Genetics Comapny Information
8.10.2 Myriad Genetics Business Overview
8.10.3 Myriad Genetics Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
8.10.4 Myriad Genetics Prostate Cancer Diagnostics Product Portfolio
8.10.5 Myriad Genetics Recent Developments
8.11 Ambry Genetics
8.11.1 Ambry Genetics Comapny Information
8.11.2 Ambry Genetics Business Overview
8.11.3 Ambry Genetics Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
8.11.4 Ambry Genetics Prostate Cancer Diagnostics Product Portfolio
8.11.5 Ambry Genetics Recent Developments
9 CONCLUDING INSIGHTS
10 APPENDIX
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
1.1 Product Definition
1.2 Global Prostate Cancer Diagnostics Market Size, 2019 VS 2023 VS 2030
1.3 Global Prostate Cancer Diagnostics Market Size (2019-2030)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 PROSTATE CANCER DIAGNOSTICS MARKET DYNAMICS
2.1 Prostate Cancer Diagnostics Industry Trends
2.2 Prostate Cancer Diagnostics Industry Drivers
2.3 Prostate Cancer Diagnostics Industry Opportunities and Challenges
2.4 Prostate Cancer Diagnostics Industry Restraints
3 PROSTATE CANCER DIAGNOSTICS MARKET BY COMPANY
3.1 Global Prostate Cancer Diagnostics Company Revenue Ranking in 2023
3.2 Global Prostate Cancer Diagnostics Revenue by Company (2019-2024)
3.3 Global Prostate Cancer Diagnostics Company Ranking, 2022 VS 2023 VS 2024
3.4 Global Prostate Cancer Diagnostics Company Manufacturing Base & Headquarters
3.5 Global Prostate Cancer Diagnostics Company, Product Type & Application
3.6 Global Prostate Cancer Diagnostics Company Commercialization Time
3.7 Market Competitive Analysis
3.7.1 Global Prostate Cancer Diagnostics Market CR5 and HHI
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2023
3.7.3 2023 Prostate Cancer Diagnostics Tier 1, Tier 2, and Tier
3.8 Mergers & Acquisitions, Expansion
4 PROSTATE CANCER DIAGNOSTICS MARKET BY TYPE
4.1 Prostate Cancer Diagnostics Type Introduction
4.1.1 Tumor Biomarker Tests
4.1.2 Imaging
4.1.3 Biopsy
4.1.4 Other
4.2 Global Prostate Cancer Diagnostics Sales Value by Type
4.2.1 Global Prostate Cancer Diagnostics Sales Value by Type (2019 VS 2023 VS 2030)
4.2.2 Global Prostate Cancer Diagnostics Sales Value by Type (2019-2030)
4.2.3 Global Prostate Cancer Diagnostics Sales Value Share by Type (2019-2030)
5 PROSTATE CANCER DIAGNOSTICS MARKET BY APPLICATION
5.1 Prostate Cancer Diagnostics Application Introduction
5.1.1 Age Below
5.1.2 Age 55-75
5.1.3 Age Above
5.2 Global Prostate Cancer Diagnostics Sales Value by Application
5.2.1 Global Prostate Cancer Diagnostics Sales Value by Application (2019 VS 2023 VS 2030)
5.2.2 Global Prostate Cancer Diagnostics Sales Value by Application (2019-2030)
5.2.3 Global Prostate Cancer Diagnostics Sales Value Share by Application (2019-2030)
6 PROSTATE CANCER DIAGNOSTICS MARKET BY REGION
6.1 Global Prostate Cancer Diagnostics Sales Value by Region: 2019 VS 2023 VS 2030
6.2 Global Prostate Cancer Diagnostics Sales Value by Region (2019-2030)
6.2.1 Global Prostate Cancer Diagnostics Sales Value by Region: 2019-2024
6.2.2 Global Prostate Cancer Diagnostics Sales Value by Region (2025-2030)
6.3 North America
6.3.1 North America Prostate Cancer Diagnostics Sales Value (2019-2030)
6.3.2 North America Prostate Cancer Diagnostics Sales Value Share by Country, 2023 VS 2030
6.4 Europe
6.4.1 Europe Prostate Cancer Diagnostics Sales Value (2019-2030)
6.4.2 Europe Prostate Cancer Diagnostics Sales Value Share by Country, 2023 VS 2030
6.5 Asia-Pacific
6.5.1 Asia-Pacific Prostate Cancer Diagnostics Sales Value (2019-2030)
6.5.2 Asia-Pacific Prostate Cancer Diagnostics Sales Value Share by Country, 2023 VS 2030
6.6 Latin America
6.6.1 Latin America Prostate Cancer Diagnostics Sales Value (2019-2030)
6.6.2 Latin America Prostate Cancer Diagnostics Sales Value Share by Country, 2023 VS 2030
6.7 Middle East & Africa
6.7.1 Middle East & Africa Prostate Cancer Diagnostics Sales Value (2019-2030)
6.7.2 Middle East & Africa Prostate Cancer Diagnostics Sales Value Share by Country, 2023 VS 2030
7 PROSTATE CANCER DIAGNOSTICS MARKET BY COUNTRY
7.1 Global Prostate Cancer Diagnostics Sales Value by Country: 2019 VS 2023 VS 2030
7.2 Global Prostate Cancer Diagnostics Sales Value by Country (2019-2030)
7.2.1 Global Prostate Cancer Diagnostics Sales Value by Country (2019-2024)
7.2.2 Global Prostate Cancer Diagnostics Sales Value by Country (2025-2030)
7.3 USA
7.3.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.3.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.3.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.4 Canada
7.4.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.4.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.4.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.5 Germany
7.5.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.5.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.5.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.6 France
7.6.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.6.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.6.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.7 U.K.
7.7.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.7.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.7.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.8 Italy
7.8.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.8.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.8.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.9 Netherlands
7.9.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.9.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.9.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.10 Nordic Countries
7.10.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.10.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.10.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.11 China
7.11.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.11.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.11.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.12 Japan
7.12.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.12.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.12.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.13 South Korea
7.13.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.13.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.13.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.14 Southeast Asia
7.14.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.14.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.14.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.15 India
7.15.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.15.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.15.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.16 Australia
7.16.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.16.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.16.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.17 Mexico
7.17.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.17.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.17.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.18 Brazil
7.18.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.18.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.18.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.19 Turkey
7.19.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.19.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.19.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.20 Saudi Arabia
7.20.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.20.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.20.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
7.21 UAE
7.21.1 Global Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030)
7.21.2 Global Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030
7.21.3 Global Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030
8 COMPANY PROFILES
8.1 OPKO
8.1.1 OPKO Comapny Information
8.1.2 OPKO Business Overview
8.1.3 OPKO Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
8.1.4 OPKO Prostate Cancer Diagnostics Product Portfolio
8.1.5 OPKO Recent Developments
8.2 Genomic Health
8.2.1 Genomic Health Comapny Information
8.2.2 Genomic Health Business Overview
8.2.3 Genomic Health Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
8.2.4 Genomic Health Prostate Cancer Diagnostics Product Portfolio
8.2.5 Genomic Health Recent Developments
8.3 Abbott
8.3.1 Abbott Comapny Information
8.3.2 Abbott Business Overview
8.3.3 Abbott Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
8.3.4 Abbott Prostate Cancer Diagnostics Product Portfolio
8.3.5 Abbott Recent Developments
8.4 Beckman Coulter
8.4.1 Beckman Coulter Comapny Information
8.4.2 Beckman Coulter Business Overview
8.4.3 Beckman Coulter Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
8.4.4 Beckman Coulter Prostate Cancer Diagnostics Product Portfolio
8.4.5 Beckman Coulter Recent Developments
8.5 Siemens Healthcare
8.5.1 Siemens Healthcare Comapny Information
8.5.2 Siemens Healthcare Business Overview
8.5.3 Siemens Healthcare Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
8.5.4 Siemens Healthcare Prostate Cancer Diagnostics Product Portfolio
8.5.5 Siemens Healthcare Recent Developments
8.6 bioMeriux
8.6.1 bioMeriux Comapny Information
8.6.2 bioMeriux Business Overview
8.6.3 bioMeriux Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
8.6.4 bioMeriux Prostate Cancer Diagnostics Product Portfolio
8.6.5 bioMeriux Recent Developments
8.7 Roche
8.7.1 Roche Comapny Information
8.7.2 Roche Business Overview
8.7.3 Roche Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
8.7.4 Roche Prostate Cancer Diagnostics Product Portfolio
8.7.5 Roche Recent Developments
8.8 MDx Health
8.8.1 MDx Health Comapny Information
8.8.2 MDx Health Business Overview
8.8.3 MDx Health Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
8.8.4 MDx Health Prostate Cancer Diagnostics Product Portfolio
8.8.5 MDx Health Recent Developments
8.9 DiaSorin
8.9.1 DiaSorin Comapny Information
8.9.2 DiaSorin Business Overview
8.9.3 DiaSorin Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
8.9.4 DiaSorin Prostate Cancer Diagnostics Product Portfolio
8.9.5 DiaSorin Recent Developments
8.10 Myriad Genetics
8.10.1 Myriad Genetics Comapny Information
8.10.2 Myriad Genetics Business Overview
8.10.3 Myriad Genetics Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
8.10.4 Myriad Genetics Prostate Cancer Diagnostics Product Portfolio
8.10.5 Myriad Genetics Recent Developments
8.11 Ambry Genetics
8.11.1 Ambry Genetics Comapny Information
8.11.2 Ambry Genetics Business Overview
8.11.3 Ambry Genetics Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
8.11.4 Ambry Genetics Prostate Cancer Diagnostics Product Portfolio
8.11.5 Ambry Genetics Recent Developments
9 CONCLUDING INSIGHTS
10 APPENDIX
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
LIST OF TABLES
Table 1. Prostate Cancer Diagnostics Industry Trends
Table 2. Prostate Cancer Diagnostics Industry Drivers
Table 3. Prostate Cancer Diagnostics Industry Opportunities and Challenges
Table 4. Prostate Cancer Diagnostics Industry Restraints
Table 5. Global Prostate Cancer Diagnostics Revenue by Company (US$ Million) & (2019-2024)
Table 6. Global Prostate Cancer Diagnostics Revenue Share by Company (2019-2024)
Table 7. Global Prostate Cancer Diagnostics Company Ranking, 2022 VS 2023 VS 2024 & (US$ Million)
Table 8. Global Prostate Cancer Diagnostics Key Company Manufacturing Base & Headquarters
Table 9. Global Prostate Cancer Diagnostics Company, Product Type & Application
Table 10. Global Prostate Cancer Diagnostics Company Commercialization Time
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global Prostate Cancer Diagnostics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2023)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Major Companies of Tumor Biomarker Tests
Table 15. Major Companies of Imaging
Table 16. Major Companies of Biopsy
Table 17. Major Companies of Other
Table 18. Global Prostate Cancer Diagnostics Sales Value by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Prostate Cancer Diagnostics Sales Value by Type (2019-2024) & (US$ Million)
Table 20. Global Prostate Cancer Diagnostics Sales Value by Type (2025-2030) & (US$ Million)
Table 21. Global Prostate Cancer Diagnostics Sales Value Share by Type (2019-2024)
Table 22. Global Prostate Cancer Diagnostics Sales Value Share by Type (2025-2030)
Table 23. Major Companies of Age Below 55
Table 24. Major Companies of Age 55-75
Table 25. Major Companies of Age Above 75
Table 26. Global Prostate Cancer Diagnostics Sales Value by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 27. Global Prostate Cancer Diagnostics Sales Value by Application (2019-2024) & (US$ Million)
Table 28. Global Prostate Cancer Diagnostics Sales Value by Application (2025-2030) & (US$ Million)
Table 29. Global Prostate Cancer Diagnostics Sales Value Share by Application (2019-2024)
Table 30. Global Prostate Cancer Diagnostics Sales Value Share by Application (2025-2030)
Table 31. Global Prostate Cancer Diagnostics Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 32. Global Prostate Cancer Diagnostics Sales Value by Region (2019-2024) & (US$ Million)
Table 33. Global Prostate Cancer Diagnostics Sales Value Share by Region (2019-2024)
Table 34. Global Prostate Cancer Diagnostics Sales Value by Region (2025-2030) & (US$ Million)
Table 35. Global Prostate Cancer Diagnostics Sales Value Share by Region (2025-2030)
Table 36. Global Prostate Cancer Diagnostics Sales Value by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 37. Global Prostate Cancer Diagnostics Sales Value by Country (2019-2024) & (US$ Million)
Table 38. Global Prostate Cancer Diagnostics Sales Value Market Share by Country (2019-2024)
Table 39. Global Prostate Cancer Diagnostics Sales Value by Country (2025-2030) & (US$ Million)
Table 40. Global Prostate Cancer Diagnostics Sales Value Market Share by Country (2025-2030)
Table 41. OPKO Company Information
Table 42. OPKO Business Overview
Table 43. OPKO Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 44. OPKO Prostate Cancer Diagnostics Product Portfolio
Table 45. OPKO Recent Development
Table 46. Genomic Health Company Information
Table 47. Genomic Health Business Overview
Table 48. Genomic Health Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 49. Genomic Health Prostate Cancer Diagnostics Product Portfolio
Table 50. Genomic Health Recent Development
Table 51. Abbott Company Information
Table 52. Abbott Business Overview
Table 53. Abbott Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 54. Abbott Prostate Cancer Diagnostics Product Portfolio
Table 55. Abbott Recent Development
Table 56. Beckman Coulter Company Information
Table 57. Beckman Coulter Business Overview
Table 58. Beckman Coulter Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 59. Beckman Coulter Prostate Cancer Diagnostics Product Portfolio
Table 60. Beckman Coulter Recent Development
Table 61. Siemens Healthcare Company Information
Table 62. Siemens Healthcare Business Overview
Table 63. Siemens Healthcare Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 64. Siemens Healthcare Prostate Cancer Diagnostics Product Portfolio
Table 65. Siemens Healthcare Recent Development
Table 66. bioMeriux Company Information
Table 67. bioMeriux Business Overview
Table 68. bioMeriux Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 69. bioMeriux Prostate Cancer Diagnostics Product Portfolio
Table 70. bioMeriux Recent Development
Table 71. Roche Company Information
Table 72. Roche Business Overview
Table 73. Roche Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 74. Roche Prostate Cancer Diagnostics Product Portfolio
Table 75. Roche Recent Development
Table 76. MDx Health Company Information
Table 77. MDx Health Business Overview
Table 78. MDx Health Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 79. MDx Health Prostate Cancer Diagnostics Product Portfolio
Table 80. MDx Health Recent Development
Table 81. DiaSorin Company Information
Table 82. DiaSorin Business Overview
Table 83. DiaSorin Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 84. DiaSorin Prostate Cancer Diagnostics Product Portfolio
Table 85. DiaSorin Recent Development
Table 86. Myriad Genetics Company Information
Table 87. Myriad Genetics Business Overview
Table 88. Myriad Genetics Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 89. Myriad Genetics Prostate Cancer Diagnostics Product Portfolio
Table 90. Myriad Genetics Recent Development
Table 91. Ambry Genetics Company Information
Table 92. Ambry Genetics Business Overview
Table 93. Ambry Genetics Prostate Cancer Diagnostics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Ambry Genetics Prostate Cancer Diagnostics Product Portfolio
Table 95. Ambry Genetics Recent Development
Table 96. Research Programs/Design for This Report
Table 97. Authors List of This Report
Table 98. Secondary Sources
Table 99. Primary Sources
Table 1. Prostate Cancer Diagnostics Industry Trends
Table 2. Prostate Cancer Diagnostics Industry Drivers
Table 3. Prostate Cancer Diagnostics Industry Opportunities and Challenges
Table 4. Prostate Cancer Diagnostics Industry Restraints
Table 5. Global Prostate Cancer Diagnostics Revenue by Company (US$ Million) & (2019-2024)
Table 6. Global Prostate Cancer Diagnostics Revenue Share by Company (2019-2024)
Table 7. Global Prostate Cancer Diagnostics Company Ranking, 2022 VS 2023 VS 2024 & (US$ Million)
Table 8. Global Prostate Cancer Diagnostics Key Company Manufacturing Base & Headquarters
Table 9. Global Prostate Cancer Diagnostics Company, Product Type & Application
Table 10. Global Prostate Cancer Diagnostics Company Commercialization Time
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global Prostate Cancer Diagnostics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2023)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Major Companies of Tumor Biomarker Tests
Table 15. Major Companies of Imaging
Table 16. Major Companies of Biopsy
Table 17. Major Companies of Other
Table 18. Global Prostate Cancer Diagnostics Sales Value by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Prostate Cancer Diagnostics Sales Value by Type (2019-2024) & (US$ Million)
Table 20. Global Prostate Cancer Diagnostics Sales Value by Type (2025-2030) & (US$ Million)
Table 21. Global Prostate Cancer Diagnostics Sales Value Share by Type (2019-2024)
Table 22. Global Prostate Cancer Diagnostics Sales Value Share by Type (2025-2030)
Table 23. Major Companies of Age Below 55
Table 24. Major Companies of Age 55-75
Table 25. Major Companies of Age Above 75
Table 26. Global Prostate Cancer Diagnostics Sales Value by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 27. Global Prostate Cancer Diagnostics Sales Value by Application (2019-2024) & (US$ Million)
Table 28. Global Prostate Cancer Diagnostics Sales Value by Application (2025-2030) & (US$ Million)
Table 29. Global Prostate Cancer Diagnostics Sales Value Share by Application (2019-2024)
Table 30. Global Prostate Cancer Diagnostics Sales Value Share by Application (2025-2030)
Table 31. Global Prostate Cancer Diagnostics Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 32. Global Prostate Cancer Diagnostics Sales Value by Region (2019-2024) & (US$ Million)
Table 33. Global Prostate Cancer Diagnostics Sales Value Share by Region (2019-2024)
Table 34. Global Prostate Cancer Diagnostics Sales Value by Region (2025-2030) & (US$ Million)
Table 35. Global Prostate Cancer Diagnostics Sales Value Share by Region (2025-2030)
Table 36. Global Prostate Cancer Diagnostics Sales Value by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 37. Global Prostate Cancer Diagnostics Sales Value by Country (2019-2024) & (US$ Million)
Table 38. Global Prostate Cancer Diagnostics Sales Value Market Share by Country (2019-2024)
Table 39. Global Prostate Cancer Diagnostics Sales Value by Country (2025-2030) & (US$ Million)
Table 40. Global Prostate Cancer Diagnostics Sales Value Market Share by Country (2025-2030)
Table 41. OPKO Company Information
Table 42. OPKO Business Overview
Table 43. OPKO Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 44. OPKO Prostate Cancer Diagnostics Product Portfolio
Table 45. OPKO Recent Development
Table 46. Genomic Health Company Information
Table 47. Genomic Health Business Overview
Table 48. Genomic Health Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 49. Genomic Health Prostate Cancer Diagnostics Product Portfolio
Table 50. Genomic Health Recent Development
Table 51. Abbott Company Information
Table 52. Abbott Business Overview
Table 53. Abbott Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 54. Abbott Prostate Cancer Diagnostics Product Portfolio
Table 55. Abbott Recent Development
Table 56. Beckman Coulter Company Information
Table 57. Beckman Coulter Business Overview
Table 58. Beckman Coulter Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 59. Beckman Coulter Prostate Cancer Diagnostics Product Portfolio
Table 60. Beckman Coulter Recent Development
Table 61. Siemens Healthcare Company Information
Table 62. Siemens Healthcare Business Overview
Table 63. Siemens Healthcare Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 64. Siemens Healthcare Prostate Cancer Diagnostics Product Portfolio
Table 65. Siemens Healthcare Recent Development
Table 66. bioMeriux Company Information
Table 67. bioMeriux Business Overview
Table 68. bioMeriux Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 69. bioMeriux Prostate Cancer Diagnostics Product Portfolio
Table 70. bioMeriux Recent Development
Table 71. Roche Company Information
Table 72. Roche Business Overview
Table 73. Roche Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 74. Roche Prostate Cancer Diagnostics Product Portfolio
Table 75. Roche Recent Development
Table 76. MDx Health Company Information
Table 77. MDx Health Business Overview
Table 78. MDx Health Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 79. MDx Health Prostate Cancer Diagnostics Product Portfolio
Table 80. MDx Health Recent Development
Table 81. DiaSorin Company Information
Table 82. DiaSorin Business Overview
Table 83. DiaSorin Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 84. DiaSorin Prostate Cancer Diagnostics Product Portfolio
Table 85. DiaSorin Recent Development
Table 86. Myriad Genetics Company Information
Table 87. Myriad Genetics Business Overview
Table 88. Myriad Genetics Prostate Cancer Diagnostics Revenue (US$ Million) and Gross Margin (2019-2024)
Table 89. Myriad Genetics Prostate Cancer Diagnostics Product Portfolio
Table 90. Myriad Genetics Recent Development
Table 91. Ambry Genetics Company Information
Table 92. Ambry Genetics Business Overview
Table 93. Ambry Genetics Prostate Cancer Diagnostics Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Ambry Genetics Prostate Cancer Diagnostics Product Portfolio
Table 95. Ambry Genetics Recent Development
Table 96. Research Programs/Design for This Report
Table 97. Authors List of This Report
Table 98. Secondary Sources
Table 99. Primary Sources
LIST OF FIGURES
Figure 1. Prostate Cancer Diagnostics Product Picture
Figure 2. Global Prostate Cancer Diagnostics Market Size (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Prostate Cancer Diagnostics Market Size (2019-2030) & (US$ Million)
Figure 4. Global Prostate Cancer Diagnostics Company Revenue Ranking in 2023 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2023 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 7. Tumor Biomarker Tests Picture
Figure 8. Imaging Picture
Figure 9. Biopsy Picture
Figure 10. Other Picture
Figure 11. Global Prostate Cancer Diagnostics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 12. Global Prostate Cancer Diagnostics Sales Value Share 2019 VS 2023 VS 2030
Figure 13. Global Prostate Cancer Diagnostics Sales Value Share by Type (2019-2030)
Figure 14. Age Below 55 Picture
Figure 15. Age 55-75 Picture
Figure 16. Age Above 75 Picture
Figure 17. Global Prostate Cancer Diagnostics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 18. Global Prostate Cancer Diagnostics Sales Value Share 2019 VS 2023 VS 2030
Figure 19. Global Prostate Cancer Diagnostics Sales Value Share by Application (2019-2030)
Figure 20. Global Prostate Cancer Diagnostics Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Figure 21. Global Prostate Cancer Diagnostics Sales Value Share by Region: 2019 VS 2023 VS 2030
Figure 22. North America Prostate Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)
Figure 23. North America Prostate Cancer Diagnostics Sales Value Share by Country (%), 2023 VS 2030
Figure 24. Europe Prostate Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)
Figure 25. Europe Prostate Cancer Diagnostics Sales Value Share by Country (%), 2023 VS 2030
Figure 26. Asia-Pacific Prostate Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)
Figure 27. Asia-Pacific Prostate Cancer Diagnostics Sales Value Share by Country (%), 2023 VS 2030
Figure 28. Latin America Prostate Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)
Figure 29. Latin America Prostate Cancer Diagnostics Sales Value Share by Country (%), 2023 VS 2030
Figure 30. Middle East & Africa Prostate Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)
Figure 31. Middle East & Africa Prostate Cancer Diagnostics Sales Value Share by Country (%), 2023 VS 2030
Figure 32. USA Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 33. USA Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 34. USA Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 35. Canada Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 36. Canada Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 37. Canada Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 38. Germany Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 39. Germany Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 40. Germany Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 41. France Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 42. France Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 43. France Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 44. U.K. Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 45. U.K. Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 46. U.K. Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 47. Italy Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 48. Italy Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 49. Italy Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 50. Netherlands Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 51. Netherlands Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 52. Netherlands Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 53. Nordic Countries Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 54. Nordic Countries Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 55. Nordic Countries Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 56. China Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 57. China Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 58. China Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 59. Japan Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 60. Japan Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 61. Japan Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 62. South Korea Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 63. South Korea Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 64. South Korea Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 65. Southeast Asia Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 66. Southeast Asia Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 67. Southeast Asia Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 68. India Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 69. India Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 70. India Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 71. Australia Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 72. Australia Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 73. Australia Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 74. Mexico Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 75. Mexico Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 76. Mexico Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 77. Brazil Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 78. Brazil Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 79. Brazil Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 80. Turkey Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 81. Turkey Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 82. Turkey Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 83. Saudi Arabia Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 84. Saudi Arabia Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 85. Saudi Arabia Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 86. UAE Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 87. UAE Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 88. UAE Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 89. Years Considered
Figure 90. Research Process
Figure 91. Key Executives Interviewed
Figure 1. Prostate Cancer Diagnostics Product Picture
Figure 2. Global Prostate Cancer Diagnostics Market Size (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Prostate Cancer Diagnostics Market Size (2019-2030) & (US$ Million)
Figure 4. Global Prostate Cancer Diagnostics Company Revenue Ranking in 2023 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2023 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 7. Tumor Biomarker Tests Picture
Figure 8. Imaging Picture
Figure 9. Biopsy Picture
Figure 10. Other Picture
Figure 11. Global Prostate Cancer Diagnostics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 12. Global Prostate Cancer Diagnostics Sales Value Share 2019 VS 2023 VS 2030
Figure 13. Global Prostate Cancer Diagnostics Sales Value Share by Type (2019-2030)
Figure 14. Age Below 55 Picture
Figure 15. Age 55-75 Picture
Figure 16. Age Above 75 Picture
Figure 17. Global Prostate Cancer Diagnostics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 18. Global Prostate Cancer Diagnostics Sales Value Share 2019 VS 2023 VS 2030
Figure 19. Global Prostate Cancer Diagnostics Sales Value Share by Application (2019-2030)
Figure 20. Global Prostate Cancer Diagnostics Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Figure 21. Global Prostate Cancer Diagnostics Sales Value Share by Region: 2019 VS 2023 VS 2030
Figure 22. North America Prostate Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)
Figure 23. North America Prostate Cancer Diagnostics Sales Value Share by Country (%), 2023 VS 2030
Figure 24. Europe Prostate Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)
Figure 25. Europe Prostate Cancer Diagnostics Sales Value Share by Country (%), 2023 VS 2030
Figure 26. Asia-Pacific Prostate Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)
Figure 27. Asia-Pacific Prostate Cancer Diagnostics Sales Value Share by Country (%), 2023 VS 2030
Figure 28. Latin America Prostate Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)
Figure 29. Latin America Prostate Cancer Diagnostics Sales Value Share by Country (%), 2023 VS 2030
Figure 30. Middle East & Africa Prostate Cancer Diagnostics Sales Value (2019-2030) & (US$ Million)
Figure 31. Middle East & Africa Prostate Cancer Diagnostics Sales Value Share by Country (%), 2023 VS 2030
Figure 32. USA Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 33. USA Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 34. USA Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 35. Canada Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 36. Canada Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 37. Canada Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 38. Germany Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 39. Germany Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 40. Germany Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 41. France Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 42. France Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 43. France Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 44. U.K. Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 45. U.K. Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 46. U.K. Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 47. Italy Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 48. Italy Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 49. Italy Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 50. Netherlands Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 51. Netherlands Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 52. Netherlands Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 53. Nordic Countries Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 54. Nordic Countries Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 55. Nordic Countries Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 56. China Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 57. China Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 58. China Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 59. Japan Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 60. Japan Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 61. Japan Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 62. South Korea Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 63. South Korea Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 64. South Korea Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 65. Southeast Asia Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 66. Southeast Asia Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 67. Southeast Asia Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 68. India Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 69. India Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 70. India Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 71. Australia Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 72. Australia Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 73. Australia Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 74. Mexico Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 75. Mexico Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 76. Mexico Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 77. Brazil Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 78. Brazil Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 79. Brazil Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 80. Turkey Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 81. Turkey Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 82. Turkey Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 83. Saudi Arabia Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 84. Saudi Arabia Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 85. Saudi Arabia Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 86. UAE Prostate Cancer Diagnostics Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 87. UAE Prostate Cancer Diagnostics Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 88. UAE Prostate Cancer Diagnostics Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 89. Years Considered
Figure 90. Research Process
Figure 91. Key Executives Interviewed
